Sanofi gets rated buy today, agreeing with bullish ratings from the Wall Street and SA analysts' consensus. With a diverse ...

Sanofi said this morning that its pipeline includes 12 potential blockbuster drugs that could generate ... sales this year from an ever-lengthening list of indications associated with type 2 ...

Sanofi has joined a growing list of drugmakers going after alpha-synuclein targeting drugs for Parkinson's disease, licensing a bispecific antibody from South Korea's ABL Bio in a deal that could ...

Among Sanofi’s rare disease drugs, new rare blood disorder drug Altuviiio ... Just released: Experts distill 7 elite stocks from the current list of 220 Zacks Rank #1 Strong Buys.

The FDA last year turned away the companies' application and asked for additional efficacy data. Regeneron and Sanofi said the resubmission adds results from an additional Phase 3 study of Dupixent in ...

French drug major Sanofi (SNY) and Regeneron Pharmaceuticals, Inc. (REGN) announced Friday that the U.S. Food and Drug Administration ...